Filing Analysis
Cross Country Healthcare, Inc. announced that stockholders approved a merger agreement to take the company private. As a result of the merger with KL Criss Cross Intermediate, LLC, the company will be delisted from NASDAQ and deregistered as a public entity.
🚩 Red Flags
- Company will be delisted from NASDAQ and deregistered under the Exchange Act upon completion of the merger.
📋 Key Facts
- Special meeting held on July 16, 2026.
- Proposal 1 (Merger Agreement) was approved by stockholders with 23,356,105 votes in favor.
- Proposal 2 (Advisory Merger-Related Compensation) was approved with 20,281,587 votes in favor.
- Quorum was established with 23,378,853 shares represented (approx. 72.36% of outstanding shares).
- The merger is expected to close in the third quarter of 2026, subject to customary closing conditions and regulatory approvals.
- Upon completion, CCRN will become a wholly-owned subsidiary of Parent and will be delisted from NASDAQ.
Cross Country Healthcare is supplementing its proxy statement following demand letters and two filed lawsuits (Malone v. Cross Country and Walsh v. Cross Country) alleging deficient disclosures regarding a proposed merger with KL Criss Cross Intermediate, LLC. The company denies the allegations but is voluntarily updating disclosures to mitigate legal risks ahead of a July 16, 2026, stockholder vote.
🚩 Red Flags
- Active litigation seeking to enjoin a proposed merger.
- Significant discrepancy between the transaction's implied EBITDA multiple (4.8x-7.5x) and historical sector precedent transactions (mean 10.7x).
- Shareholder demand letters alleging deficient disclosures/misrepresentations.
📋 Key Facts
- Special meeting of stockholders scheduled for July 16, 2026, to vote on the merger with KL Criss Cross Intermediate, LLC (Parent).
- Two lawsuits filed in New York Supreme Court: Malone v. Cross Country Healthcare and Walsh v. Cross Country Healthcare.
- Lawsuits allege material omissions/misrepresentations in the Proxy Statement and seek an injunction against the merger.
- The company is voluntarily supplementing the proxy statement to address 'demand letters' from purported stockholders.
- BofA Securities applied a reference range of 4.8x to 7.5x EV/EBITDA for the transaction analysis, significantly lower than historical precedent transactions in the sector (8.9x to 11.5x).
- The company expects to complete the merger in Q3 2026 if approved.
Cross Country Healthcare, Inc. announced that the HSR Act waiting period has expired for its proposed merger with KL Criss Cross Intermediate, LLC and the simultaneous sale of its locums business division to All Star Healthcare Solutions. The merger is expected to close in Q3 2026, pending shareholder approval on July 16, 2026.
🚩 Red Flags
- Transaction involves a divestiture of a business division (Locums) as part of the merger structure.
📋 Key Facts
- HSR Act waiting period expired as of 11:59 p.m. ET on June 22, 2026.
- The transaction involves a merger with KL Criss Cross Intermediate, LLC and the sale of the Locums business division to All Star Healthcare Solutions (an affiliate of Parent).
- A special meeting of shareholders is scheduled for July 16, 2026, to vote on the merger.
- The merger is expected to close in the third quarter of calendar year 2026.
Cross Country Healthcare, Inc. announced its financial results for the first quarter ended March 31, 2026. The information was furnished via a press release attached as Exhibit 99.1.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The report was filed on May 7, 2026, under Items 2.02 and 7.01.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934.
- William J. Burns, Executive Vice President & Chief Financial Officer, signed the filing.
Cross Country Healthcare (CCRN) has entered into a definitive merger agreement to be acquired by KL Criss Cross Intermediate, LLC, an affiliate of Knox Lane LP, for $13.25 per share in cash. Upon completion, the company will become a privately held entity and its common stock will be delisted from Nasdaq.
🚩 Red Flags
- Potential antitrust complications necessitating the divestiture of the locums business division.
- Extended regulatory timeline with the 'End Date' potentially stretching to April 2027.
- Significant termination fee ($14.2M) may deter other potential bidders.
📋 Key Facts
- Merger consideration is $13.25 per share in cash, without interest.
- The agreement includes a potential 'Locums Transaction' involving the sale of the company's locums business division to an affiliate of the Parent to satisfy antitrust requirements.
- A termination fee of $14,213,075 is payable by the Company under certain circumstances, including the acceptance of a superior proposal.
- A Parent Regulatory Termination Fee of $14,213,075 is payable to the Company if the deal fails due to antitrust hurdles.
- The transaction is not subject to a financing condition and is backed by equity commitments from funds affiliated with Knox Lane LP.
- The 'End Date' for the merger is five months from May 6, 2026, with potential extensions to April 6, 2027, for regulatory approvals.
Cross Country Healthcare, Inc. filed a Form 8-K to furnish a press release under Regulation FD. The filing serves as a formal disclosure of information previously released to the public via a press release on April 17, 2026.
📋 Key Facts
- The filing was made on April 17, 2026, under Item 7.01 (Regulation FD Disclosure).
- A press release was issued on the same date and furnished as Exhibit 99.1.
- The report was signed by William J. Burns, Executive Vice President & Chief Financial Officer.
- The information provided is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Cross Country Healthcare Inc. promoted Amiee Hawkins to Chief Operating Officer, effective March 28, 2026. Ms. Hawkins is a long-tenured internal executive who has held various leadership roles at the company since 2014, most recently serving as Chief Solutions and Operations Officer.
📋 Key Facts
- Amiee Hawkins appointed Chief Operating Officer effective March 28, 2026
- Ms. Hawkins has been with the company since 2014, previously serving as Chief Solutions and Operations Officer and Senior VP of Enterprise Operations
- No changes were made to Ms. Hawkins' compensation or employment agreement in connection with the appointment
- The appointment was approved by the Board of Directors on March 25, 2026
Phil Noe ceased serving as Chief Information Officer of Cross Country Healthcare effective March 10, 2026. The company entered into a separation agreement providing $205,975 in severance and a short-term consulting agreement through May 31, 2026, to assist with technology transition.
📋 Key Facts
- Phil Noe's departure as CIO was effective March 10, 2026
- Severance amount is $205,975, representing six months of base salary
- Consulting agreement established from March 11, 2026, to May 31, 2026, at a rate of $198.04 per hour
- Severance is contingent on a waiver and release of claims and will be paid bi-weekly over six months
Cross Country Healthcare announced the simultaneous departures of its Chief Accounting Officer, James V. Redd III, and its Chief Information Officer, Phil Noe, effective March 10, 2026. The company promoted Marvin Veizaga, its current Group VP and Corporate Controller, to succeed Mr. Redd as the new Senior Vice President and Chief Accounting Officer.
🚩 Red Flags
- Simultaneous departure of two high-level executives (CAO and CIO) on the same effective date.
📋 Key Facts
- James V. Redd III departed as SVP and Chief Accounting Officer effective March 10, 2026.
- Phil Noe departed as Chief Information Officer effective March 10, 2026.
- Marvin Veizaga was appointed as the new SVP and Chief Accounting Officer.
- Mr. Veizaga's new compensation includes a $340,000 base salary, a 50% short-term incentive target, and a 50% long-term incentive target.
- The company stated there were no disagreements regarding accounting practices or financial reporting.
- Mr. Veizaga has been with the company since 2015 and previously served as a Senior Auditor at Deloitte & Touche LLP.
Cross Country Healthcare, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The results were disclosed via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- Filing date: March 4, 2026
- Reporting period: Fourth quarter and full year ended December 31, 2025
- Items reported: Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure)
- The information in the filing is furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act
Cross Country Healthcare, Inc. issued a press release on February 23, 2026, and furnished the information under Regulation FD. This is a standard regulatory filing used to disclose public communications or investor updates.
📋 Key Facts
- The filing was triggered by Item 7.01 Regulation FD Disclosure.
- A press release was issued on February 23, 2026, and included as Exhibit 99.1.
- The report was signed by William J. Burns, Executive Vice President & Chief Financial Officer.
- The information in Item 7.01 is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Cross Country Healthcare, Inc. filed an 8-K to furnish a press release issued on February 12, 2026, under Regulation FD Disclosure.
📋 Key Facts
- The filing was made on February 12, 2026.
- The company is furnishing information via Exhibit 99.1 (Press Release).
- Information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 liability.
Cross Country Healthcare, Inc. has announced the date for its 2026 Annual Meeting of Stockholders and provided updated deadlines for stockholder proposals and director nominations due to an advanced meeting schedule.
📋 Key Facts
- The 2026 Annual Meeting of Stockholders is scheduled for May 11, 2026.
- The meeting will be held virtually; website details to be provided in the proxy statement around March 31, 2026.
- Deadline for stockholder proposals eligible for inclusion under Rule 14a-8: March 11, 2026.
- Deadline for written notice of business proposals or director nominations per Bylaws: February 10, 2026.
- Deadline for stockholders to solicit proxies for non-company nominees (Universal Proxy Rules): March 12, 2026.
Cross Country Healthcare, Inc. filed an amendment to its previous 8-K to disclose the specific compensation terms for newly appointed President and CEO Kevin C. Clark.
🚩 Red Flags
- Significant severance obligations (2 years of salary + bonus) represent a potential liability in the event of leadership change.
📋 Key Facts
- Kevin C. Clark was appointed President and CEO on December 15, 2025.
- The employment agreement (Clark Agreement) was entered into on January 2, 2026.
- Initial term is three years, expiring December 14, 2028, with automatic one-year renewals.
- Annual base salary is set at $950,000.
- Target Annual Cash Incentive Program (ACIP) bonus for 2026 is 100% of base; increasing to 125% in 2027.
- Long-term incentive plan target awards increase annually from 300% of base in 2026 to 325% in 2027/2028.
- Severance package includes two years of base salary and accelerated vesting of equity if terminated without cause or for good reason.
Cross Country Healthcare, Inc. announced the separation of its President and CEO, John A. Martins, effective December 14, 2025. Co-founder Kevin C. Clark has been appointed as the new President and CEO while retaining his role as Chairman.
🚩 Red Flags
- Sudden leadership transition (CEO separation)
- Significant cash severance obligations for departing CEO
- Reduction in Board size
📋 Key Facts
- John A. Martins separated from the company as CEO and left the Board of Directors on Dec 14, 2025.
- Severance for Mr. Martins includes 2 years of base salary ($875,000/year) plus 2x average bonus, 24 months of benefits, and full vesting of equity awards.
- Kevin C. Clark (Chairman and co-founder) appointed President and CEO effective Dec 14, 2025.
- The Board size was reduced from seven members to six following the departure.
- Terms for Mr. Clark's new employment agreement have not yet been determined.
Cross Country Healthcare, Inc. held its Annual Meeting of Stockholders on December 9, 2025. The meeting resulted in the successful election of seven directors and the ratification of Deloitte & Touche as the company's independent auditor for the fiscal year ending December 31, 2025.
📋 Key Facts
- Annual Meeting held on December 9, 2025.
- Seven directors were elected to one-year terms: Kevin C. Clark, Dwayne Allen, Venkat Bhamidipati, W. Larry Cash, Gale Fitzgerald, John A. Martins, and Dr. Janice E. Nevin.
- Ratification of Deloitte & Touche as the independent registered public accounting firm for FY2025 was approved with 25,759,187 votes in favor.
- Compensation of named executive officers was approved on an advisory (non-binding) basis.
Cross Country Healthcare, Inc. announced the termination of its merger agreement with Aya Holdings II Inc. due to the failure to consummate the transaction by the required end date. The company is set to receive a $20 million cash termination fee from the Parent.
🚩 Red Flags
- Failed merger: A significant strategic event (acquisition) failed to close after a full year of negotiation/process.
- Uncertainty regarding future growth strategy following the collapse of the acquisition plan.
📋 Key Facts
- Merger Agreement terminated effective December 4, 2025.
- Termination caused by failure of the merger to be consummated prior to the expiration of the end date.
- Parent (Aya Holdings II Inc.) must pay a $20 million cash termination fee to the Company within two business days.
- The original Merger Agreement was entered into on December 3, 2024.
Cross Country Healthcare, Inc. filed an 8-K to announce its quarterly earnings results for the period ending September 30, 2025. The filing serves as a formal notice that financial results have been released via press release.
📋 Key Facts
- The company issued a press release on November 12, 2025, regarding quarterly results.
- Reporting period: Quarter ended September 30, 2025.
- The filing is made pursuant to Items 2.02 and 7.01 of Form 8-K.
Cross Country Healthcare, Inc. has announced the scheduling of its 2025 Annual Meeting for December 9, 2025, contingent upon the completion of a pending merger with Aya Healthcare, Inc. The filing also establishes deadlines for stockholder proposals and director nominations.
📋 Key Facts
- The 2025 Annual Meeting is scheduled for December 9, 2025, via virtual-only format.
- The meeting will only occur if the pending merger with Aya Healthcare, Inc. (the 'Aya Merger') is not completed prior to that date.
- The Company expects the Aya Merger to close in Q4 2025.
- If the merger completes, Cross Country Healthcare will become a wholly owned subsidiary of Aya Healthcare, Inc., and the Annual Meeting will be canceled.
- Deadline for stockholder proposals/nominations: October 10, 2025.
Cross Country Healthcare, Inc. has extended the 'End Date' of its merger agreement with Aya Holdings II Inc. from September 3, 2025, to December 3, 2025. The extension is due to ongoing regulatory reviews by the FTC.
🚩 Red Flags
- Regulatory scrutiny: The merger is currently under review by the FTC (Second Request), which has caused a delay in the original timeline.
- Timeline uncertainty: While an extension was granted, the deal's consummation remains contingent on overcoming regulatory hurdles.
📋 Key Facts
- The End Date for the merger was automatically extended from September 3, 2025, to December 3, 2025.
- The Company and Aya have both certified substantial compliance with the FTC's 'Second Request' as of August 29, 2025.
- The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions and regulatory approvals.
Cross Country Healthcare, Inc. has filed an 8-K to announce its quarterly earnings results for the period ending June 30, 2025. The filing serves as a formal notification that financial results have been released via press release.
📋 Key Facts
- The company issued a press release on August 6, 2025, regarding its quarterly earnings.
- Reporting period covered is the quarter ended June 30, 2025.
- The filing includes Exhibit 99.1 containing the full press release.
Cross Country Healthcare, Inc. filed an 8-K to announce its quarterly results for the period ended March 31, 2025. The filing serves as a formal mechanism to furnish earnings data via a press release.
📋 Key Facts
- The company issued a press release on May 7, 2025, announcing financial results for the quarter ended March 31, 2025.
- The filing is made pursuant to Items 2.02 (Results of Operations and Financial Condition) and 7.01 (Regulation FD Disclosure).
- Financial data was provided via Exhibit 99.1.
Cross Country Healthcare, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024. The filing serves as a formal notification of the earnings release issued on March 5, 2025.
📋 Key Facts
- Company announced Q4 and Full Year 2024 financial results on March 5, 2025.
- The reporting period ended December 31, 2024.
- Information was furnished under Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure).
Cross Country Healthcare, Inc. (CCRN) has successfully obtained stockholder approval for its merger with Aya Holdings II Inc. As a result of the approved merger, CCRN will be taken private and delisted from the NASDAQ.
🚩 Red Flags
- Delisting: The company's common stock will be delisted from the NASDAQ Stock Market LLC upon closing.
- Deregistration: The company will be deregistered under the Securities Exchange Act of 1934, removing it from public reporting requirements.
📋 Key Facts
- Stockholders approved Proposal 1 (Merger Agreement) with 25,660,468 votes in favor.
- The merger involves Aya Holdings II Inc. (Parent), Spark Merger Sub One Inc., and Aya Healthcare, Inc.
- Quorum was established by holders of 25,680,210 shares, representing ~78.25% of outstanding common stock as of the record date.
- The merger is expected to close in the second half of 2025, subject to customary closing conditions and regulatory approvals.
- Upon completion, CCRN will be a wholly-owned subsidiary of Parent and no longer publicly held.
Cross Country Healthcare reported that the FTC has issued a 'Second Request' for additional information regarding its proposed merger with Aya Holdings II Inc. This regulatory hurdle extends the HSR Act waiting period, pushing the expected closing date to the second half of 2025.
🚩 Red Flags
- Regulatory delay: The FTC's 'Second Request' indicates deeper scrutiny into potential antitrust issues, which can lead to prolonged timelines or required divestitures.
- Execution risk: The extended timeline increases the window for market volatility or changes in macroeconomic conditions that could impact the deal.
📋 Key Facts
- The company is in the process of being acquired by Aya Holdings II Inc. (Parent) and Aya Healthcare, Inc. (Aya).
- On February 20, 2025, the FTC issued a 'Second Request' for additional information regarding the merger.
- The HSR Act waiting period is extended until 30 days after substantial compliance with the Second Request.
- The company now expects the merger to close in the second half of 2025.
- The transaction remains subject to stockholder approval and customary closing conditions.
Cross Country Healthcare, Inc. has entered into a definitive merger agreement with Aya Holdings II Inc. (Parent) to be acquired in an all-cash transaction.
🚩 Red Flags
- The company will be delisted and deregistered upon completion of the merger.
- Contains a 'no-shop' provision with a fiduciary out for superior proposals.
📋 Key Facts
- Merger consideration is $18.61 per share in cash.
- The merger will result in the delisting of CCRN from the Nasdaq Global Select Market.
- The deal includes a $20 million termination fee payable by either party under specific circumstances.
- The transaction is subject to stockholder approval and customary closing conditions, including antitrust clearance (HSR Act).
- Termination date (End Date) is set for September 3, 2025, with an extension to December 3, 2025, if delayed by antitrust approvals.
Cross Country Healthcare, Inc. filed an 8-K to announce its quarterly earnings results for the period ended September 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly results (Item 2.02).
- Results pertain to the quarter ended September 30, 2024.
- The company issued a press release on November 6, 2024, as Exhibit 99.1.
The company filed an 8-K to furnish a press release issued on October 24, 2024. The filing itself contains no substantive financial or corporate news beyond the notification of the press release under Regulation FD.
📋 Key Facts
- Filing date: October 24, 2024
- The report is filed pursuant to Item 7.01 (Regulation FD Disclosure)
- A press release was issued on October 24, 2024, as Exhibit 99.1
- No specific financial data or material agreements were detailed in the text of the 8-K itself
Cross Country Healthcare, Inc. filed an 8-K to furnish a press release issued on October 18, 2024, under Regulation FD Disclosure.
📋 Key Facts
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- A press release was issued on October 18, 2024, and is attached as Exhibit 99.1.
- The information provided under Item 7.01 is furnished but not 'filed' for purposes of liability under Section 18 of the Exchange Act.
Cross Country Healthcare, Inc. filed an 8-K to furnish a press release issued on August 21, 2024, pursuant to Regulation FD Disclosure.
📋 Key Facts
- The filing was made on August 21, 2024.
- The company is furnishing information via Exhibit 99.1 (Press Release).
- Information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 liability.
Cross Country Healthcare, Inc. filed an 8-K to announce its quarterly earnings results for the period ended June 30, 2024. The filing serves as a formal announcement of the company's financial performance via a press release.
📋 Key Facts
- The company issued a press release on July 31, 2024, regarding quarterly results for the period ended June 30, 2024.
- The filing was signed by William J. Burns, Executive Vice President & Chief Financial Officer.
- Information is being furnished under Item 2.02 and Item 7.01 of Form 8-K.
Cross Country Healthcare, Inc. has amended its existing Asset-Based Lending (ABL) Credit Agreement with Wells Fargo Bank N.A. The amendment provides greater flexibility regarding how cash share repurchases impact the company's fixed charge coverage ratio.
🚩 Red Flags
- None identified; the amendment appears to be a technical modification to debt covenants rather than an indication of distress.
📋 Key Facts
- Amendment No. 7 to the ABL Credit Agreement was executed on July 29, 2024.
- The amendment allows all cash-paid share repurchases occurring after June 30, 2024, to be excluded from 'restricted payments' in the fixed charge coverage ratio calculation.
- This exclusion is conditional: it only applies if there is no revolving ABL balance outstanding at the time of the repurchase (excluding interest and fees).
- The facility may be further syndicated at a later date.
Cross Country Healthcare, Inc. filed an 8-K to furnish a press release issued on July 11, 2024, pursuant to Regulation FD Disclosure.
📋 Key Facts
- The filing is made under Item 7.01 (Regulation FD Disclosure).
- A press release was issued on July 11, 2024, and is attached as Exhibit 99.1.
- The information provided in the press release is furnished but not 'filed' for purposes of Section 18 liability.
The company filed an 8-K to furnish a press release issued on May 23, 2024. The filing itself contains no substantive financial or structural changes and serves as a placeholder for the attached exhibit.
📋 Key Facts
- Filing date: May 23, 2024
- The report is filed under Item 7.01 (Regulation FD Disclosure)
- Information in Exhibit 99.1 is furnished but not 'filed' for purposes of Section 18 liability
Cross Country Healthcare, Inc. announced that stockholders approved the 2024 Omnibus Incentive Plan during the Annual Meeting held on May 14, 2024. This plan serves as a successor to the 2020 Plan and aims to align employee interests with stockholders through various equity-based awards.
📋 Key Facts
- Stockholders approved the '2024 Omnibus Incentive Plan' on May 14, 2024.
- The plan increases the number of shares reserved for equity-based awards by 2,400,000 shares of Common Stock.
- Awards under the plan can include stock options, stock appreciation rights, stock units, and cash awards.
- The plan is valid until May 13, 2034.
- The plan was adopted to replace the '2020 Omnibus Incentive Plan'.
Cross Country Healthcare, Inc. held its Annual Meeting of Stockholders on May 14, 2024. The meeting resulted in the successful election of eight directors and the ratification of Deloitte & Touche as the independent auditor.
📋 Key Facts
- Annual Meeting of Stockholders held on May 14, 2024.
- Eight directors were elected for one-year terms ending in 2025 or until successors are qualified: Kevin C. Clark, Dwayne Allen, Venkat Bhamidipati, W. Larry Cash, Gale Fitzgerald, John A. Martins, Dr. Janice E. Nevin, and Mark Perlberg.
- Ratification of Deloitte & Touche as the independent registered public accounting firm for fiscal year ending Dec 31, 2024 was approved (31,129,700 'For' votes).
- Compensation of named executive officers was approved on an advisory basis.
- The Company's 2024 Omnibus Incentive Plan was approved by stockholders.
The company filed an 8-K to furnish a press release issued on May 13, 2024, pursuant to Regulation FD Disclosure. The filing does not contain specific financial results or material changes in this text, only the notice of the press release.
📋 Key Facts
- Filing date: May 13, 2024
- The report is filed under Item 7.01 (Regulation FD Disclosure)
- A press release was issued on May 13, 2024, as Exhibit 99.1
Cross Country Healthcare reported that a single managed service program customer filed for Chapter 11 bankruptcy on May 6, 2024. This event is expected to result in an undetermined bad debt charge in Q2 2024, following a prior deterioration in accounts receivable aging from this client.
🚩 Red Flags
- Significant credit risk concentration: A single customer's bankruptcy is impacting $20 million of receivables.
- Material impact to upcoming earnings: The company explicitly states it will take an associated charge in Q2 2024.
- Uncertainty regarding recovery: While the amount is estimated at $20M, the final bad debt charge remains 'yet to be determined'.
📋 Key Facts
- A single managed service program customer filed for Chapter 11 bankruptcy on May 6, 2024.
- The company is owed an estimated $20 million (net of reserves and subcontractor receivables) by this customer.
- The company expects to take a bad debt charge related to this amount in the second quarter of 2024.
- The deterioration was previously noted as a driver for increased bad debt expense in 2023.
The company issued a press release via Regulation FD disclosure on May 3, 2024. The filing itself contains no substantive financial or structural changes and serves only to furnish the attached press release.
📋 Key Facts
- Filed on May 3, 2024
- The filing is under Item 7.01 (Regulation FD Disclosure)
- Information provided in Exhibit 99.1 is furnished but not 'filed' for purposes of Section 18 liability
- Signed by William J. Burns, Executive Vice President & Chief Financial Officer
Cross Country Healthcare, Inc. issued an 8-K to announce its quarterly earnings results for the period ended March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly results (Item 2.02).
- Results pertain to the quarter ending March 31, 2024.
- A press release containing the financial results was issued on May 1, 2024.
The company filed an 8-K to furnish a press release issued on April 10, 2024, pursuant to Regulation FD Disclosure. The filing does not contain substantive financial news or material changes in its own text, merely referencing Exhibit 99.1.
📋 Key Facts
- The company issued a press release on April 10, 2024.
- Information is being furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for liability purposes under Section 18 of the Exchange Act.
The company filed an 8-K to furnish a press release pursuant to Regulation FD disclosure requirements. The filing does not contain substantive financial news or material changes in its own text, referring instead to Exhibit 99.1.
📋 Key Facts
- Filing date: February 23, 2024
- The report is filed under Item 7.01 (Regulation FD Disclosure)
- Information provided in the press release (Exhibit 99.1) is furnished but not 'filed' for purposes of Section 18 liability.
Cross Country Healthcare, Inc. announced the departure of its Chief Commercial Officer, Daniel J. White, effective March 31, 2024. The separation includes a six-month salary continuation agreement.
🚩 Red Flags
- Departure of a C-suite officer (Chief Commercial Officer) can sometimes signal internal friction or shifts in commercial strategy, though no specific cause was cited.
📋 Key Facts
- Daniel J. White is departing from his role as Chief Commercial Officer.
- The effective date of departure is March 31, 2024.
- The separation agreement provides for continued base salary payments for six months following the effective date.
Cross Country Healthcare, Inc. issued an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2023.
📋 Key Facts
- Report date: February 21, 2024
- Reporting period: Fourth quarter and full year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
The company filed an 8-K to furnish a press release pursuant to Regulation FD disclosure requirements. The filing itself contains no substantive financial or structural changes, acting merely as a vehicle to provide information via Exhibit 99.1.
📋 Key Facts
- Filed on February 1, 2024
- The filing is for the purpose of furnishing a press release under Item 7.01 (Regulation FD Disclosure)
- Information provided in the exhibit is not considered 'filed' for purposes of Section 18 liability